Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) — Capital Reinvestment Ratio

Latest as of September 2025: 97.08x

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) has a Capital Reinvestment Ratio of 97.08x as of September 2025, meaning it reinvests 97% of its operating cash flow (CN¥543.69K) in capital expenditures (CN¥52.78 Million). Check Suzhou Zelgen Biopharmaceuticals Co Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

97.08x

Capex / Operating Cash Flow

Operating Cash Flow

CN¥543.69K

CNY

Capital Expenditures

CN¥52.78 Million

CNY

Data as of

Sep 2025

Most recent filing

Suzhou Zelgen Biopharmaceuticals Co Ltd Capital Reinvestment Ratio (2024–2024)

This chart tracks Suzhou Zelgen Biopharmaceuticals Co Ltd's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) cash flow conversion.

Annual Capital Reinvestment Ratio for Suzhou Zelgen Biopharmaceuticals Co Ltd (2024–2024)

Year-by-year Capital Reinvestment Ratio for Suzhou Zelgen Biopharmaceuticals Co Ltd from 2024 to 2024. See Suzhou Zelgen Biopharmaceuticals Co Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Year	Reinvestment Ratio	Operating CF (CNY)	Capital Expenditures	YoY Change
2024	2.50x	CN¥38.20 Million	CN¥95.69 Million	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow